California's Endonovo Therapeutics recently raised $10 million to help propel development of its electromagnetic devices designed to spur regeneration of damaged tissue and organs.
Philips Healthcare sealed a new patient telemonitoring tech deal with Partners HealthCare, the largest hospital group in Massachusetts and among the most influential providers in the nation.
Israel's Lumenis is bucking the hesitance of many medical device companies to pursue the public markets and is moving ahead with its IPO plans. The maker of minimally invasive medical lasers released further details in a recent regulatory filing, noting that it wants to sell 6.3 million shares and raise approximately $100 million.
At the beginning of February, Smith & Nephew announced a deal to buy ArthroCare, a Texas company that specializes in sports medicine joint repair, for $1.7 billion. Now, the world knows a little more about what Smith & Nephew will be getting for their money if the deal closes midyear as planned.
Medtronic launched a new crossing catheter in Europe to treat peripheral artery disease. The device recently received a European CE mark, but has yet to win FDA clearance, the company said in a statement.
Ariosa Diagnostics won certification from the New York Department of Health to begin selling its Harmony prenatal and reporting test results to New York healthcare providers, a big step in the company's efforts to grow its market for the test.
Orthofix International is confronting yet another indignity in what has been a tough couple of years. The Texas orthopedic device maker disclosed that Nasdaq smacked it with an expected delisting notice, a measure threatened months ago because the company missed filing its 2013 second-quarter financials on time.
Blood Purification Technologies won FDA clearance to begin human clinical trials of its Wearable Artificial Kidney. Testing will be conducted at several academic medical centers, the company said in a statement. Specific trial dates were not disclosed.
Amedica has priced its public offering, and in doing so has lowered expectations for the second time this week. The Utah medical device company said it will roll out of the gate with an offering of 3.5 million shares of common stock at $5.75 per share, a price much lower than the company initially proposed.
Illumina is throwing its cachet and its $1,000 genome sequencing system behind a San Francisco genomics startup incubator backed by Russian billionaire Yuri Milner.
A Teleflex subsidiary is voluntarily recalling one of its tracheal tubes because of reports that it can kink during use and cut off a patient's air supply. The FDA slapped its Class I recall designation on the Pennsylvania company's action, meaning the defect carries with it a risk of major injury or death.
California's Miramar Labs nailed down $10 million in new Series D funding that it will use to boost sales efforts for its CE marked medical device that eliminates sweat glands under the arms. Aisling Capital, Cross Creek Capital, Domain Associates, Morgenthaler Ventures and RusnanoMedInvest all participated in the round.
For Biosensors International, stability has become a good-enough result in fiscal 2014. As with the previous quarter, Q3 has given the Singapore device company more of the same--a steady growth in revenue, but lower net profit due to restructuring and other one-time expenses.
California biopharmaceutical giant Amgen got smacked with an FDA warning letter alleging quality system manufacturing violations in some of its drug/device combo products. These prefilled syringes and related devices are prepped for osteoporosis and autoimmune treatments.
Sequoia Capital is the lead investor in a $10 million funding round for Guardant Health, a California cancer diagnostics startup.
Dirty surgical tools may have once again placed neurological patients at risk for Creutzfeldt-Jakob disease (CJD), a rare and fatal degenerative condition. It's something that medical device companies are probably watching pretty closely, depending on how the affected medical center managed its operating room.
Italian diagnostics company DiaSorin Group unveiled a new test to detect Rotavirus in stool samples in Europe, hoping to cash in on a €10 million ($13.7 million) a year market, reported Reuters.
A Baxter Healthcare plant in Illinois failed to put in place adequate quality control practices in the manufacture of HomeChoice dialysis and iPump pain management systems, the FDA tells the company in a warning letter.
Demark's Dako and Amgen like working together so much that they're extending their relationship. They've agreed to develop a new molecular diagnostic test in an expansion of an alliance that first began two years ago.
As the FDA keeps pushing for more pediatric-friendly devices, Smith Medical has taking a small but crucial step that helps answer that call.